Emily graduated from the University of Liverpool in 2013, then spent three years working in small animal practice.
Having developed a keen interest in ophthalmology, Emily began studying for the BSAVA postgraduate certificate in ophthalmology, then moved to the Animal Health Trust in Suffolk to complete a specialist internship in veterinary ophthalmology.
She then pursued her specialist residency training at the Royal Veterinary College in London and became a Diplomate of the European College of Veterinary Ophthalmology earlier this year.
She said: “I have a particular interest in microsurgery, particularly corneal and lens surgery, while I also enjoy feline ophthalmology and am interested in uveitis and glaucoma.”
Vim graduated from the University of Bristol in 2005 and spent seven years in a first opinion small animal, mixed and exotics practice in Bristol, gaining his RCVS certificate in veterinary ophthalmology in 2012.
He qualified as an advanced practitioner since 2015, working solely as an ophthalmologist at large private referral hospitals before embarking on a European College of Veterinary Ophthalmologists (ECVO) residency programme at Langford Vets, University of Bristol, in 2019.
He completed his final year of residency training and Master of Veterinary Medicine degree at the Royal Veterinary College (RVC) in August and is due to sit the ECVO certifying board exams next spring.
Vim said: “I always knew I wanted to become an ophthalmologist, even before I started vet school! It’s a wonderful opportunity to join the NDSR ophthalmology team.
“I’m interested in all areas of ophthalmology and across all species. I have a particular interest in feline ophthalmology, infectious keratitis, ocular manifestations of systemic disease and wildlife/exotics species ophthalmology.
“I’m also passionate about teaching and mentoring junior vets and undergraduate students. I’ve been the veterinary intern mentor or director for more than 40 interns over the years and I hope to get involved with NDSR’s renowned internship programme.”
Vim will also be doing one day a week working at Southfields Veterinary Specialists at its recently-opened Basildon hospital.
www.ndsr.co.uk
Merial has launched Supleneo flex, a nutraceutical supplement designed to be part of a Total Joint Health programme for dogs, administered once daily.
Merial says the new product supports its market position as a leading force in canine pain management, supported by the canine NSAID Previcox.
According to the company, Supleneo flex is suitable for all breeds, sizes and ages, and contains three key ingredients associated with joint health: glucosamine hydrochloride, chondroitin sulphate and mixed tocopherols (Vitamin E). It is designed to be used as part of an all-round joint care programme, alongside nutrition, weight management and exercise.
Merial says the soft chews are highly palatable and when tested against a range of competitor products, a significant difference was observed, with Supleneo flex readily taken and preferred by dogs.1
Supleneo flex is supported by printed and digital materials to help with owner education, including a waiting room video and an online information website at www.supleneoflex.co.uk for clients.
For veterinary surgeons, Merial is offering product advertising support and a loyalty programme.
For more information, telephone Merial on 0870 6000 123 or contact your Territory Manager.
The new product contains a combination of Omega-3s, toxin binders and antioxidants which the company claims flush out toxins, aid blood flow to the kidneys and maintain kidney architecture.
Matthew Shaw, Managing Director of nutravet said: "We’re really excited to launch nutraren, it’s a product our team have been working on for some time to make sure we have developed the best renal product for vets to recommend to their clients.
"Using independent trial data, we’ve been able to develop a unique formulation for nutraren containing 100% natural ingredients to benefit a pet’s long-term kidney health."
Authorised veterinary practices can now order nutraren from nutravet.
For more information, contact nutravet on 0845 604 1688, visit: www.nutravet.co.uk or email: info@nutravet.co.uk.
The website now contains a range of information on Alfaxan including user experiences, sections on best practice anaesthesia, webinars and details of Jurox’s anaesthesia roadshows.
The webinars include a presentation which explains how to use Alfaxan to achieve the best anaesthetic experience for the patient. There is also series of short online webinars on rabbit anaesthesia:
An online CPD certificate will be issued to veterinary professionals who have viewed each webinar, after they have taken a short online questionnaire.
The Alfaxan website also offers downloadable resources such as the new Considerations for Anaesthetising Rabbits expert panel guidelines booklet, AVA Anaesthetic Safety Checklist Implemenation manual, AVA Anaesthetic Safety Checklist and Alfaxan resource guides, user guides, dose charts and monitoring charts.
Richard Beckwith, country manager of Jurox (UK) Ltd, said: "Our new Alfaxan website is an educational hub that enables veterinary professionals to learn more about best practice anaesthesia and how this can be implemented in their own clinics. With Alfaxan’s new pet rabbit indication we have included an emphasis on rabbit anaesthesia and how this differs from anaesthesia in cats and dogs."
For further information, visit www.alfaxan.co.uk, contact your local Jurox technical sales representative, telephone the customer services team on 0800 500 3171 or e-mail: info@jurox.co.uk.
The company says that practices transferring to its pet health plan portal will be able to take greater control of their pet health plans and benefit from a range of innovative services for the same cost. They include the VMD-approved Post2Pet home delivery service, a messaging system to advise clients on applying products, attending appointments or renewing prescriptions, reporting to give practice leaders the insights they need to drive plan performance, the ability for pet owners to sign up online rather than visit the practice, and 24/7 access to a marketing hub and the Premier Vet Alliance Learning Academy.
Premier Vet Alliance’s Business Development Director Andy Taylor said: "We are excited to be offering our high performing Premier Pet Care Plan to the many new practices joining us following our acquisition of Simplyhealth’s animal health business.
"We are working to make the transition seamless and believe that our new customers will be delighted at the expanded range of functionality our portal offers them, together with the reduced administrative burden. We will continue to invest in its development to ensure that all of our customers can be sure that their pet health plan offers the most powerful set of tools and services available to help them drive up the profitability of their practice, while offering gold standard care to their patients and peace of mind to their clients."
For more information, visit: https://premiervetalliance.com/uk/
NOAH's third Brexit Barometer found that where in the last report, 17% of its members reported feeling 'very' or 'somewhat pessimistic', that figure has now risen to 32%.
Meanwhile, the National Audit Office has revealed in its 'Progress in Implementing EU Exit' report that Defra has been prevented from consulting with the veterinary market by DExEU.
The report states that Defra is one of the government departments most affected by EU Exit and looks in detail at four of Defra’s main workstreams, including ‘import of animals and animal products’ and ‘exports of animals and animal products’.
In an accompanying press release, the National Audit Office notes that in a no-deal scenario there will be a significant increase in certificates needing to be processed by veterinary surgeons. It says: "Without enough vets, consignments of food could be delayed at the border or prevented from leaving the UK. Defra intended to start engaging with the veterinary industry in April 2018, but has not been permitted to do so and now plans to launch an emergency recruitment campaign in October to at least meet minimum levels of vets required. It plans to meet any remaining gaps through the use of non-veterinarians to check records and processes that do not require veterinary judgement."
The BVA says it has previously outlined concerns about the potential for diluting veterinary certification, and is calling on the Government to fully engage with the veterinary profession before making any changes that could impact the UK’s ability to trade animal products safely and in line with high animal welfare standards.
The RCVS has also weighed in. Amanda Boag, RCVS President, said: "We are glad to see the National Audit Office report recognises that a ‘no deal’ Brexit scenario would be likely to reduce the supply of EU veterinary surgeons to the UK and cause uncertainty regarding the status of those EU veterinary surgeons who are currently living and working in the UK and that this would have a particularly serious impact on necessary veterinary work in public health and certification.
"We continue to engage with Defra and, like the BVA, we want to emphasise the essential need for Government to consult with the profession to ensure their plans meet requirements, including maintenance of the high veterinary standards for which the UK is known. We also want to highlight the importance and value of the veterinary profession in other areas of society including caring for pets, horses and farm animals as well as research, education and industry, and emphasise the impact of workforce shortages on all sectors."
The equine events will initially take place at Rossdales Equine Hospital in Suffolk on 22nd October and at Ashbrook Veterinary Hospital in Cheshire on 5th December.
The roadshow will see a range of speakers renowned in the fields of equine veterinary medicine and QI share practical examples of improving outcomes for equine patients. Interactive workshops, real-life scenarios and case studies will show how QI techniques can be applied in practice to help teams prevent and respond to errors.
Confirmed speakers include Professor Debra Archer, Head of Equine Surgery and Professor in Equine Surgery at the University of Liverpool, Dr Alice Bird, Senior Clinical Anaesthetist at the Animal Health Trust and Dr Rachel Dean, Director of Clinical Research and Excellence in Practice, VetPartners.
President Elect of BEVA, Tim Mair, said: "There are many challenges to being an equine vet and running a successful equine practice. Even in large practices and equine hospitals, there is a risk that we operate in our own little bubble and assume that what we are doing is best practice, whereas in reality we could often do a better job.
"Clinical governance and quality improvement are tools that allow us to critically appraise our day-to-day work and identify ways in which we can continuously improve what we do – to the benefit of our patients and clients, as well as to ourselves."
The canine hip dysplasia roadshow will begin on 9th October in Gatwick, Surrey.
The event will review the condition prevalent in dogs, how best to investigate it and the available treatment options. Case examples will be used to show how the evidence can be evaluated, explain how to measure treatment outcomes and show how the use of checklists can help minimise potential errors.
It will be hosted by Mark Morton, RCVS Specialist in Small Animal Surgery (Orthopaedics). He said: "As vets we probably all undertake bits of QI on a day-to-day basis (whether we realise it or not!) but there is so much more we can do to embed it into our clinical work. Checklists, treatment guidelines and clinical auditing significantly improve our patient care and our outcomes.
"Whilst looking at hip dysplasia and the treatment options in detail, hopefully this roadshow will show how we can apply these ideas to improve our management of this condition as well as using them elsewhere.”
For the full programme of each event and to buy tickets, visit bit.ly/RCVSKnowledgeEvents.
Anyone interested in booking an RCVS Knowledge roadshow for their region can do so by contacting ebvm@rcvsknowledge.org.
The survey, which takes about 5 minutes (I timed it), is designed to canvas opinion about the priorities for learning and development.
Rich Casey, Junior Vice President of the VMG (pictured right), said: "From marketing to HR to financial planning and all points in between, today’s veterinary leaders require expertise in every aspect of running a successful business.
"We want to create a truly valuable, constructive and evidence-based CPD calendar for next year. Views from those working in the profession will help us to fully understand what good leadership and management look like in the veterinary world and we will then make sure that the programme promotes best practice in these important areas. We thank everyone who takes the time to complete the survey."
The survey can be accessed here: https://www.surveymonkey.co.uk/r/VETCPDPR
Norbrook Laboratories has launched a long-acting cattle bolus which it says will reduce the risk of Milk Fever.
According to the company, Calcitrace D3 is the first and only long-acting bolus to offer slow and fast releasing calcium to provide sustained calcium levels for 48 to 72 hours. In addition, Calcitrace D3 provides Magnesium, Phosphate and Vitamin D3 making it the most comprehensive bolus available.
Calcitrace D3 is smooth gelatin coated bolus with a rounded tip designed for easier administration. Norbrook says it is smaller than other boluses making it less likely to cause trauma on the orpharynx during administration.
Dr Barry McInerney, Norbrook's GB Veterinary Advisor said: "Milk Fever is a common metabolic disorder in dairy cattle which generally affects older, high producing cows and is caused by a rapid decrease in calcium concentrations in the blood just before calving. It is estimated that 3-10% of cows are affected by Milk Fever with a cost of more than £200 per incident so it is crucial that farmers and vets reduce the risk as effectively as possible.
"Norbrook's new Calcitrace D3 bolus which should be administered just before calving, provides higher calcium blood levels during the critical 12 - 48 hour post calving period and provides sustained increased levels for well beyond 48 hours. With the addition of Magnesium, Phosphate and Vitamin D3, Calcitrace D3 provides additional protection against Milk Fever."
Andrew Hillan MVB MRCVS, Director of Veterinary Sciences at Norbrook, led the development of Calcitrace D3. He said: "The launch of Calcitrace D3 is another illustration of the very high quality of technical expertise that exists within our research and development department and underlines Norbrook's commitment to developing high quality and innovative products. It comes from a strong and exciting pipeline of new products which we will bring to the market over the next couple of years."
The aim of the study was to assess the efficacy and adverse effect profile of each individual AED by analysing all available data published and then evaluating how reliable it was.
The researchers gathered, screened and assessed all the information published in peer-reviewed journals and publications. The individual studies were then evaluated based on the quality of evidence, study design, study group sizes, subject enrolment quality and overall risk of bias, as well as the efficacy and safety outcome measures.
Lead-author, Marios Charalambous from Ghent University, said: "We recruited systematic methods to combine, compare and summarise the results of independent studies and, therefore, create more objective and reliable conclusions based on the current evidence. It was a time-consuming, demanding and challenging process, and we hope we provided the clinicians now with essential information which they can use for daily practice."
The researchers found that much of the evidence for the medical treatment of feline epilepsy was based on below-par reporting of efficacy and adverse effect, worse than what was formerly reported in dogs.
The lack of good quality evidence led authors to conclude that it would be: "...rather inaccurate to make definite statements on which one [AED] should be considered as a first or second choice in terms of both efficacy and safety profile. However, if clinicians focus on AED’s efficacy, phenobarbital can be used as first-choice monotherapy and if they focus on AED’s safety, imepitoin or levetiracetam can be used."
Holger Volk, Head of the Department Clinical Science and Services and Professor of Veterinary Neurology and Neurosurgery at the RVC, said: "Not only does this study offer a new perspective on the management of feline epilepsy, but also highlights the importance of the need for trials which provide high quality evidence in order to have more reliable and objective results about the efficacy and safety of the AEDs in feline epilepsy."
The study was published in BMC Veterinary Research (https://doi.org/10.1186/s12917-018-1386-3).
The trial, which was conducted by a UK-French team of researchers from PBD Biotech and Biosellal, is being presented at the European Association of Veterinary Laboratory Diagnosticians (EAVLD) Congress in Brussels today.
Current tests only allow the reliable detection of Mycobacterium avium subspecies paratuberculosis (MAP) from 18-24 month calves and are unable to distinguish between active and passive infection.
For the 16-month trial, calves from three different herds and born from MAP-positive and MAP-negative cows were tested monthly using PBD Biotech’s Actiphage Rapid kit and Biosellal’s Bio-T kit MAP PCR on blood samples, and the same PCR on faeces.
Researchers say the trial proves that early detection of live MAP infection is possible, and paves the way for improved Johne’s disease monitoring and control measures on farms.
Co-Author Dr Ben Swift, Research Fellow in Antimicrobial Resistance at the Royal Veterinary College and R&D Director at PBD Biotech, said: "Young animals are highly susceptible to infection and being able to identify Johne’s disease at this early stage is key to controlling disease spread.
The trial showed that the sensitivity and specificity of Actiphage enables detection of lower levels of MAP than the current culture methods, and provides results in 6 hours rather than weeks."
The Actiphage Rapid technology used in the trial identified live MAP infection at least 4 weeks’ earlier than the faecal PCR in 75% of cases: in one case, the new diagnostic detected MAP in the blood of a one-day old calf born from a MAP-positive cow.
Claire Pelletier, Directrice Générale of BioDev, consultant to Biosellal, will be presenting findings from the trial, which also showed the transient nature of the infection. She said: "The study showed that two calves, identified as MAP-positive by Actiphage-PCR on blood during the first monthly sampling didn’t shed MAP into their faeces until 10 and 11 months. This emphasises that early detection provides a short window of time that allow for control of the disease."
Other international trials using Actiphage are underway to investigate the presence of MAP in milk.
Earlier this year, the RCVS Council approved the roll-out of a more outcomes-based model of CPD to encourage veterinary professionals to engage in greater reflection on learning and development, and the impact that it has on their professional practice.
To support this approach, Council also approved the development of a new CPD recording platform designed to be more intuitive and to make it easy to record CPD in real time.
The College says the new platform – which has the working title of 'One CPD' – will be a ‘one stop shop’ CPD management solution for veterinary surgeons and nurses at all stages of their careers, including veterinary students and student veterinary nurses.
Richard Burley, RCVS Chief Technology Officer, said: "We’re excited to open up access to this powerful, next-generation, tool we’ve been building and welcome our members into an important phase of the development process. Testing with our members will be absolutely critical in delivering the very best experience possible for all those that use 'One CPD' in the future. Ease of use and truly valuable functionality are key deliverables for us and both these need the feedback of our members to perfect."
Dr Linda Prescott-Clements, RCVS Director of Education (pictured right), added: "The first stage of the development of the CPD recording platform is due to finish in October and so we are looking for a cohort of both veterinary surgeons and nurses who can spend a few months this autumn using the new platform to record and reflect on their CPD, in order to test out some of the new features which aim to make this process so much easier to do. We will consider their feedback carefully in order to improve the recording platform ready for launch in January 2020.
"The new ‘One CPD’ platform will ultimately replace the current Professional Development Record, and its use will become mandatory for recording CPD from January 2022.
"In addition to setting up the testing group, we are also looking to meet with key CPD providers for veterinary surgeons and veterinary nurses over the coming months to discuss our plans for outcomes-based CPD and the development of the recording platform in greater detail."
Veterinary surgeons who'd like to take part in the testing for the CPD app, as well as CPD providers who want to discuss the College’s CPD policy plans, should contact Jenny Soreskog-Turp, RCVS CPD Officer, on cpd@rcvs.org.uk or 020 7202 0701.
The Veterinary Workforce Summit was held last November, when 80 stakeholders from independent and corporate practices, veterinary schools, charities, government, the food hygiene sector, species associations and industry bodies came together to look at how the profession could address the workforce crisis.
Prior to the Summit, preliminary research was carried out to assess the profession's views on the workforce crisis and how it was affecting them.
Based on findings from the preliminary research, six themes around the issue of workforce shortages were identified and used to structure the discussions of the day.
These were: readiness for work; work-life balance; workplace culture; client interactions; career development; and return to work.
The day was opened by Lizzie Lockett, RCVS Chief Executive, who focused on the issues underpinning the workforce crisis:
Later in the day, delegates were divided into groups and asked to develop ideas and pitch a solution to a problem the sector is facing.
Some of the solutions that the professions might use to address the key workforce issues which came out of the pitches included:
Kate Richards, RCVS President, said: “Although the issues affecting the UK veterinary sector aren’t new, they have been exacerbated over the past few years by factors outside of the sector’s control.
"We know that putting in place solutions to address and solve the issues that the veterinary sector is facing will take time.
"We want to reiterate that the Summit was the first, albeit an incredibly important, first step in co-creating innovative solutions to workforce shortages.
"I look forward to working collaboratively with our veterinary colleagues from across the professions to bring the workforce action plan to life and work on the solutions that come out of it.”
The RCVS says the next steps from the Summit are to consider the feasibility of the suggested solutions and integrate those that seem likely to deliver effective results into an action plan, alongside other activities that are already underway.
The College says it is open to hearing additional ideas for the professions and encourages anyone who has suggestions to get in touch with Sophie Rogers, ViVet Manager, on s.rogers@rcvs.org.uk
The full Workforce Summit report can be found at www.rcvs.org.uk/publications
The anti-emetic, Cerenia (maropitant citrate), has gained licenses for use in puppies from as young as eight weeks of age and in cats from 16 weeks of age in the prevention and treatment of vomiting and reduction of nausea.
Cerenia is an NK-1 receptor antagonist which Pfizer says is effective against both peripheral and central emetic stimuli by acting on the final common pathway for emesis. It is, according to the company, the only NK-1 receptor antagonist licensed for dogs and cats.
Pfizer adds that in addition to the use for general emesis in puppies, Cerenia can also be used for chemotherapy-induced nausea in dogs. Studies in human oncology show that some patients receiving chemotherapy consider nausea to be more distressing than vomiting1. and the use of NK-1 receptor antagonists has shown clear benefits in the prevention of nausea and vomiting in chemotherapy-treated humans2. Cerenia tablets are also for the treatment for motion sickness in dogs aged 16 weeks or older, delivering claimed efficacy up to 93% without sedating the dog.
Kate Grocott, Product Manager for Cerenia, said: "Already successfully used in the treatment and prevention of vomiting and chemotherapy nausea in dogs, the new licence is a positive step forward for the prevention and early treatment of vomiting for puppies as young as eight weeks of age and cats from 16 weeks old. Being able to deploy Cerenia in these cases, will improve quality of life, and increases the likelihood of the animal voluntarily taking food and water thereby assisting in the recovery where there is underlying disease."
The new licence for treatment of cats with Cerenia is associated with the injectable form, while puppies may be treated with either an injection or tablets.
For further information, contact your Pfizer Animal Health account manager or call 0845 300 8034.
References
Merial Animal Health has launched Allevinix, a flunixin-based non-steroidal anti-inflammatory (NSAID) pain killer for cattle, pigs and horses.
Victoria Hudson, Product Manager for Merial Animal Health said: "We have positioned Allevinix as the flexible flunixin that meets your needs, because it offers flexibility in every area.
"It is the only flunixin licensed for both intramuscular and intravenous administration in cattle and we know that this will be very welcome for many vets and farmers. It can be used across cattle, pigs and horses, and it is the first injectable NSAID to come in a durable, non-breakable bottle."
Merial says Allevinix is fast-acting against inflammation, pain and fever, reaching peak plasma levels approximately 30 minutes after injection. It is available in 100ml and 250ml PET bottles and joins Ketofen as part of a range of NSAIDs available from Merial. It can also be used in conjunction with Merial's antimicrobial treatment for calf pneumonia - Zactran.
Victoria added: "We believe that vets will find this is a useful and innovative addition to the range of options that they have in terms of NSAIDs. Allevinix has a number of advantages over other flunixin products currently on the market."
Canaural contains fusidic acid, framycetin and nystatin for their antibacterial and antifungal effects against the most common organisms associated with otitis externa.
Fusidic acid has skin penetrating properties and is active against staphylococci and streptococci1. Framycetin is active against Gram negative species. Dechra says the combination of the two provides an enhanced antibacterial effect on the most common bacterial cause of canine otitis2.
Nystatin is active against malassezia and prednisolone helps to provide anti-inflammatory and anti-pruritic action.
Dechra Brand Manager Carol Morgan said: “The reintroduction of Canaural to the veterinary treatment market means that once again veterinarians have this reliable and effective treatment available to tackle one of the most common canine complaints.
"Canaural is a tried and tested product and a recent study showed that fusidic acid is highly efficacious against both methicillin sensitive and methicillin resistant strains of Staphylococcus pseudintermedius3. Canaural remains as relevant today as it has ever been."
Canaural comes in 15 ml and 25 ml bottle sizes and is now available in veterinary wholesalers.
Ceva Animal Health has introduced an improved version of Hepatosyl, its liver support supplement for horses.
Hepatosyl Plus for horses contains the same antioxidant ingredients as the original version but now also contains Silybin, the most active isomer of Silybum marianum (milk thistle)1.
According to Ceva, the addition of Silybin gives new Hepatosyl Plus a triple antioxidant approach to liver support to help neutralise free radicals within the liver. Free radicals are produced by hepatocyte mitochondria and cause oxidative damage to cell membranes, protein and DNA.
The company says Hepatosyl Plus's triple approach includes S-adenosylmethionine (SAMe), in a stable, pure and absorbable form, which is converted into the potent liver anti-oxidant glutathione and also helps to maintain bile flow; Vitamin E, which is well-known as a potent liver antioxidant, and Silybin, which works as an antioxidant by increasing cellular superoxide dismutase.
Hepatosyl Plus remains the only liver supplement to contain Vitamin K which is needed by the liver for the production of many essential clotting factors, such as factors II, VII, IX and X, making it ideally suited for pre and post anaesthetic liver support.
Ceva says an independent trial2 on horses with confirmed liver disease has demonstrated the benefits of Hepatosyl. Conducted by European Specialist in equine internal medicine Dr Tim Brazil, the trial involved seven horses of various ages and types. All animals were given Hepatosyl in addition to treatment with antimicrobials, corticosteroids, a low protein diet and vitamin B supplementation. Post SAMe supplementation tests revealed a notable reduction in raised liver enzymes, serum proteins and bile acids and the seven horses showed obvious improvements including better appetite, weight gain and demeanour.
For further product information contact Ceva Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at http://www.ceva.uk.com/
References1 Flatland B (2003) Botanicals, Vitamins and Minerals and the Liver2 Brazil T (2007) S-adenosylmethionine liver support supplement trial in horses
Vétoquinol has launched a competition to promote its NSAID Cimalgex, in which a veterinary surgeon or nurse will win (get this) an Aston Martin DB9.
In addition, Vétoquinol will be offering the winner a day's performance driving course at the Millbrook Proving Ground and £1,000 towards the costs of insurance.
To enter you need to answer some questions relating to Cimalgex. Until the end of BSAVA Congress, you can do this at the Cimalgex stand (821). Thereafter, you can enter the competition by visiting: www.CiMyDog.co.uk and answering the same questions online.
This competition will close and the winner will be announced on the last day of London Vet Show 2014.
Robert Simpson, Cimalgex Product Manager said: "Giving this beautiful DB9 to a vet or nurse in the UK is an incredibly exciting opportunity. This competition stands out as one of the most sensational and audacious I have heard of in the veterinary industry and hopefully it will create a lot of fun and excitement both at BSAVA and beyond."
Animalcare has announced the launch of Clavubactin (amoxicillin/clavulanate) for dogs and cats, presented as 4-way split tablets in three strengths to ensure optimum dosing. The three strengths (Clavubactin 50, 250 and 500) contain 50/12.5, 250/62.5 and 500/125mg of amoxicillin and clavulanic acid respectively. Clavubactin 50mg is licensed for cats and dogs. The 250 and 500mg formulation is licensed for dogs only.
According to the company, the increased combined level of active ingredients, compared to some other clavulanate-amoxicillin products on the market, achieves recommended target weight dosing (doses always kept at 12.5mg/kg), even with animals of greater weight, minimising the risk of underdosing.
The 4-way split tablets are designed to facilitate easy and accurate dosing of all sizes of dogs and cats, from 1kg bodyweight (¼ tablet Clavubactin 50) to 50kg (1 tablet Clavubactin 500) and above.
The tablets come in aluminium blister strips of ten tablets in five packaging presentations (Clavubactin 50 and 250 are available in 100 and 250 tablet packs and Clavubactin 500 in 100 tablets).
Animalcare Product Manager Tony Liepman said "Clavubactin allows for optimum target weight dosing and together with the accuracy enabled by SmartTabs easy 4-way split, this gives peace of mind to both vet and client."
The product is supported by dosage charts and dispensing envelopes (the latter is available on request).
For further information contact Animalcare on 01904 487687, speak to your regional Animalcare representative or visit www.animalcare.co.uk/contact-us.
Four new procedures have been added: cystostomy tube placement, endotracheal intubation, point-of-care ultrasound (POCUS), and wet-to-dry dressings.
The new video content, access to which is included with the printed book, has been designed as a ‘go to’ resource to reference prior to performing a procedure.
Nick Bexfield, one of the editors of the new edition, said: “We have built upon the success of the previous editions by responding to the feedback received from the BSAVA readership, and hope this new guide helps to further increase the confidence and accuracy with which these procedures are performed.”
Print copies are available through the BSAVA store, you can also access the digital version in the BSAVA Library.
Prices are £45.50 for BSAVA members; £70.00 for non-members.
The company says the new addition leverages a combination of image recognition technology, algorithms, and cloud-based deep learning AI to enable accurate, in-clinic sediment analysis of fresh urine, delivering results within minutes.
The system evaluates red and white blood cells, squamous and other epithelial cells (e.g. urothelial and renal tubular epithelial cells), hyaline and non-hyaline casts, struvite and calcium oxalate dihydrate crystals, and cocci and rod bacteria.
Zoetis says its performance is comparable to that of a clinical pathologist.
Richard Goldstein, DVM, DACVIM, DECVIM-CA, Vice President and Chief Medical Officer, Global Diagnostics Medical Affairs at Zoetis said: “Urinalysis is an essential diagnostic test for veterinary surgeons, and often a good indicator of potential wider issues.
"Having the ability to get these results faster will improve the speed and level of care teams can provide their patients, facilitating efficient medical decision-making and helping to ensure smooth workflows.
At the beginning of the hearing legal applications were made to rule that the whole proceedings should be stopped as an abuse of process on various grounds including the delay that had occurred in the matters being referred to the RCVS, and that there had been flaws in the original investigatory process.
There was also application that the evidence of one of the College’s witnesses should be excluded on the grounds that the witness had been convicted of bribery.
The Committee decided that the proceedings should continue but ruled that the statement and evidence of one witness should be excluded from the hearing based upon their conviction.
Mr Gracey faced five charges, all of which he was found guilty of. They were:
Three other charges were found not proven and one allegation was withdrawn by the RCVS.
The Committee then considered if the proven charges amounted to serious professional misconduct.
In doing so it made reference to the Code of Professional Conduct and its supporting guidance, particularly in relation to the 10 Principles of Certification.
Dr Hazel Bentall MRCVS, chairing the Committee and speaking on its behalf, said: “The Committee considered individually and cumulatively all matters it had found proved.
"It concluded that the public relies on veterinary surgeons to be honest and transparent when completing and signing forms.
"There is a public interest in being able to trust the profession to uphold high standards of probity because veterinary surgeons are trusted to play an important role in the promotion of animal health and welfare and associated human health.
"The Committee therefore concluded that cumulatively Charges 1, 2, 3 and 4 amounted to serious professional misconduct because the respondent had failed to meet the necessary high standards of honesty and transparency.
"In particular the fact that there were four separate events relating to animal welfare and public health was significant when considering what sanction to impose.”
“The Committee is satisfied that such conduct, when taken together, would be considered deplorable by other members of the profession.
"The respondent’s conduct on four occasions in respect of four animals and three conflicts of interest called into question his competence in relation to completing such forms.”
In considering the appropriate sanction for Mr Gracey, the Committee took into account both mitigating and aggravating circumstances, as well as a number of character witnesses for the respondent who highlighted his positive personal and professional qualities.
In mitigation, the Committee considered that Mr Gracey has hitherto been of good character with no previous disciplinary findings, that he had admitted some parts of the charges against him at the outset of the hearing, that he had made efforts to avoid repeating the misconduct and remediate it – this included making alternative certification arrangements for his father’s farm and taking more appropriate care with record keeping.
The Committee also acknowledged the significant lapse of time between the date of the misconduct and the hearing and the stress that had caused to Mr Gracey, as well as the insight he had shown into his misconduct.
Taking into account all the factors, the Committee decided that imposing a period of six months suspension from the Register of Veterinary Surgeons was the appropriate sanction for Mr Gracey.
Dr Bentall added: “The Committee concluded that suspension of the respondent’s registration for a period of six months was proportionate.
"The Committee considered whether a shorter period was appropriate bearing in mind the mitigating factors it had found applied in this case.
"It decided that a period of six months was proportionate and the minimum length necessary to meet the public interest balancing the seriousness of the misconduct and the mitigation.
"It decided that a shorter period of suspension would be insufficient to uphold proper standards within the profession, or to have a deterrent effect.
“The Committee was satisfied that the respondent had shown sufficient insight and efforts to remediate his misconduct and it concluded that at the end of this period of suspension he would not pose a further risk to animal welfare or public health.
"The Committee considered that the respondent was a valued veterinary surgeon with extensive farm animal experience and that a more severe sanction such as removal from the RCVS Register would not properly reflect the Committee’s findings on the scale of dishonesty and would not take account of the respondent’s mitigation.”
www.rcvs.org.uk/disciplinary
iRecall Consent Management falls into two parts: an initial three staged campaign to gain clients' consent before the 25th May deadline, then ongoing maintenance of the database, managing existing clients' communication preferences and gaining consent for new clients.
Thereafter, iRecall will cross reference consent and communication preferences for any iRecall-powered outbound marketing communication for a practice.
Practice-branded client consent requests are created in real time using live practice data and are personalised for each individual client and their pets.
Consent Management uses the company's SMARTdelivery technology to maximise response rates: first selecting the best delivery method (SMS, email or letter) for each client, based on current information in the practice management system. If a message fails to send because of an invalid number or email address, Consent Management automatically selects the next delivery method.
iRecall says Consent Management already interfaces with the six leading practice management systems, and can interface with any system on request.
Jamie Crittall, Director of Virtual Recall and himself a practice owner said: "Practices need to stop thinking that GDPR is a burden but see it as opportunity to forge stronger relationships with their clients and helping them to keep their pets healthy. Practices who treat their clients’ personal data with the same care that they show their pets will be rewarded with greater trust and loyalty, ensuring the future success of their business. Furthermore, it’s the perfect opportunity for practices to re-engage with previously lapsed clients to make them active and loyal once more - a massive value add."
For more information, visit: http://www.virtualrecall.com/
MSD Animal Health has launched Zuprevo Cattle, which contains a novel antibiotic molecule to help combat bovine respiratory disease (BRD).
Zuprevo Cattle contains the active ingredient tildipirosin (180mg/ml), a new 16-membered, tribasic macrolide unique to animal health. It is licensed for the treatment and prevention of BRD associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni.
According to MSD Animal Health livestock veterinary adviser Paul Williams MRCVS, the new product works extremely quickly in the animal, as well as offering the longest duration of activity in the lungs of all the macrolide antibiotics currently on the market. He says it is also extremely convenient to use: "Zuprevo is readily absorbed by the animal, reaching peak plasma concentrations within 23 minutes of injection. Zuprevo is readily distributed around the body and reaches lung concentration well above MIC90 for all of the three BRD target pathogens within four hours of administration. In addition, it maintains lung concentration above the MIC90 for up to 28 days, which will appeal to many practitioners."
Paul says that it is Zuprevo's 16-membered, tribasic macrolide structure that allows it to deliver these significant pharmacological benefits for the management of BRD in cattle: "Zuprevo works by diffusing into the bacterial cell where its binding action inhibits protein synthesis of the bacterial ribosome. Its unique 16-membered, tribasic structure enables enhanced penetration of the bacterial cell wall, as well as having the ability to bypass some potential bacterial resistance mechanisms."
Paul says Zuprevo also offers vets and their farmer clients important practical usage advantages: "Zuprevo is an easily syringeable solution for injection available in convenient 20ml, 50ml and 100ml vial sizes to suit different usage requirements. At a dose rate of 1ml/45kg, it offers the lowest macrolide dose volume per kg of bodyweight. At 47 days, Zuprevo also has the shortest macrolide meat withdrawal period."
Further information on this new macrolide antibiotic is available from the MSD Animal Health territory managers or by calling the company's Veterinary Services Group on 01908 685685.
Simon Wootton, Northern European Region CAG Marketing Manager at Idexx said: "It is widely accepted that 1 in 3 cats and 1 in 10 dogs will develop CKD. The adoption by IRIS of the Idexx SDMA™ renal function test is testament to its benefits, and should give vets much more time to intervene and prescribe an appropriate course of action to help improve longevity and quality of life in CKD patients."
Idexx has produced two new wall-charts for practices, intended to assist with the diagnosis, staging and treatment of CKD in dogs and cats. They are being distributed to all practices in the UK, and can also be downloaded from the Idexx website – www.idexx.eu or ordered from Idexx by ringing 00800 1234 33 99.